Document ID: chunk:federal_register_of_legislation:F2024L00217:reg:9:p1
Version: federal_register_of_legislation:F2024L00217
Segment Type: reg
Provision Reference: reg 9 (pt 1/3)
Character Range: 3980–7376

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting acute myeloid leukaemia or death from acute myeloid leukaemia with the circumstances of a person's relevant service:

(1)          having smoked tobacco products:
(a)          in an amount of at least 10 pack-years before clinical onset; and
(b)          commencing at least 5 years before clinical onset; and
(c)          if smoking has ceased before clinical onset, then that onset occurred within 15  years of cessation;
Note: one pack-year is defined in the Schedule 1 - Dictionary.
(2)          having one of the following haematological disorders at the time of clinical onset:
(a)          myelodysplastic syndrome;
(b)          myelodysplastic/myeloproliferative neoplasm;
(c)          aplastic anaemia; or
(d)          paroxysmal nocturnal haemoglobinuria.
Note 1: myelodysplastic / myeloproliferative neoplasm is defined in the Schedule 1 - Dictionary.
Note 2: myelodysplastic syndrome is also known as myelodysplastic neoplasm.
(3)          having one of the following myeloproliferative neoplasms at the time of the clinical onset of acute myeloid leukaemia:
(a)          chronic myeloid leukaemia;
(b)          essential thrombocythaemia;
(c)          polycythaemia vera;
(d)          primary myelofibrosis;
(e)          chronic eosinophilic leukaemia;
(f)           chronic neutrophilic leukaemia;
(g)          juvenile myelomonocytic leukaemia; or
(h)          myeloproliferative neoplasm, not otherwise specified.
(4)          undergoing a course of treatment with one of the following drugs at least 6 months before clinical onset and if treatment has ceased before clinical onset, then that onset occurred within 20 years of cessation:
(a)          alkylating agent;
(b)          topoisomerase II inhibitor;
(c)          azathioprine;
(d)          platinum agents; or
(e)          poly(ADP-ribose) polymerase inhibitors (PARP inhibitors).
Note: Examples of topoisomerase II inhibitors include etoposide, teniposide, mitozantrone (also known as mitoxantrone), daunorubicin, doxorubicin, epirubicin, and idarubicin. Examples of platinum agents include carboplatin, cisplatin, and oxaliplatin. Examples of PARP inhibitors include olaparib, rucaparib, niraparib, talazoparib and veliparib.
(5)          having received a cumulative equivalent dose of at least 0.01 sievert of ionising radiation to the bone marrow at least one year before the clinical onset;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
(6)          undergoing ablative treatment with radioactive iodine for cancer before clinical onset, where the first exposure occurred at least one year before clinical onset;
(7)          undergoing ablative treatment with radioactive phosphorus for a myeloproliferative neoplasm before clinical onset, where the first exposure occurred at least one year before clinical onset;
(8)          being exposed to benzene as specified:
(a)          for a cumulative total of at least 1,250 hours within a continuous period of 5 years before clinical onset; and
(b)          where the first exposure in that period occurred at least 2 years before clinical onset;
Note: being exposed to benzene as specified is defined in the Schedule 1 – Dictionary.
(9)          inhaling,